All In Biotech

Drug Trial Radar · NCT04922021

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-site, Proof of Concept Trial to Evaluate the Efficacy and Safety of LEO 138559 in Adult Subjects With Moderate to Severe Atopic Dermatitis (AD).

Last checked: Nov 20, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

58

Actual

Start

Jul 14, 2021

Primary completion

Jun 2, 2022

Study completion Sep 26, 2022

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jun 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new medicine (LEO 138559) given by injection to see if it works to treat AD and what the side effects are when compared with a placebo injection with no medical ingredient. The study will last up to 36 weeks for each participant. The study will include a treatment period of 16 weeks, during which the participants will receive the injections, followed by a period of 16 weeks without treatment with the main purpose of continuing safety evaluations. The participants will regularly visit the clinic for tests and the study doctor will evaluate their AD. The participants will also be asked to answer questions about their AD symptoms and quality of life.

Conditions

  • Atopic Dermatitis

Interventions

  • LEO 138559Drug

    LEO 138559 is an antibody given by injection just under the skin.

  • LEO 138559 placeboDrug

    LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except for the medical ingredient LEO 138559.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in EASI Score From Baseline to Week 16Time frame: Week 0 to Week 16

Locations

17 sites in 4 countries. Site status is shown where the registry gives one.

  • LEO Pharma Investigational Site

    Birmingham, Alabama

  • LEO Pharma Investigational Site

    Fountain Valley, California

  • LEO Pharma Investigational Site

    Los Angeles, California

  • LEO Pharma Investigational Site

    Doral, Florida

  • LEO Pharma Investigational Site

    Hialeah, Florida

  • LEO Pharma Investigational Site

    Markham, Ontario, Canada

  • LEO Pharma Investigational Site

    Mississauga, Ontario, Canada

  • LEO Pharma Investigational Site

    Peterborough, Ontario, Canada

  • LEO Pharma Investigational Site

    Berlin, Germany

  • LEO Pharma Investigational Site

    Dresden, Germany

  • LEO Pharma Investigational Site

    Leipzig, Germany

  • LEO Pharma Investigational Site

    Lübeck, Germany

  • LEO Pharma Investigational Site

    Krakow, Poland

  • LEO Pharma Investigational Site

    Krakow, Poland

  • LEO Pharma nvestigational Site

    Rzeszów, Poland

  • LEO Pharma Investigational Site

    Warsaw, Poland

  • LEO Pharma Investigational Site

    Wroclaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.